Table 2.
Participant vision and retinal morphology over the study period
| BCVA and retinal morphology | Time post commencement of aflibercept treatment | |||
|---|---|---|---|---|
| 6 months | 1 year | 18 months | 2 years | |
| Mean number of BCVA letters | 73.5 (9.4) | 74.3 (9.4) | 72.3 (12.0) | 73.8 (10.7) |
| Change in number of BCVA (letters), n | ||||
| Gain of ≥ 15 letters | 0 | 0 | 0 | 1 |
| Gain of 10–14 letters | 5 | 6 | 2 | 6 |
| Gain of 5–9 letters, | 5 | 9 | 11 | 7 |
| Loss or gain of < 5 letters | 14 | 8 | 8 | 8 |
| Loss of 5–9 letters | 2 | 2 | 2 | 2 |
| Loss of ≥ 10 letters | 0 | 1 | 3 | 2 |
| Mean CFT, µm | 298.6 (58.7) | 295.4 (47.6) | 286.7 (42.6) | 290.1 (61.9) |
| Change in CFT, n | ||||
| Reduced by ≥ 50 μm | 16 | 15 | 16 | 15 |
| Reduced/increased by < 50 μm | 10 | 9 | 8 | 8 |
| Increased by ≥ 50 μm | 0 | 1 | 2 | 1 |
| Mean CSVol, mm3 | 8.7 (0.9) | 8.5 (0.8) | 8.5 (0.7) | 8.5 (0.8) |
| Change in CSVol, n | ||||
| Reduced by ≥ 1.0 mm3 | 15 | 15 | 16 | 15 |
| Reduced/increased by < 1.0 mm3 | 11 | 11 | 8 | 9 |
| Increased by ≥ 1.0 mm3 | 0 | 0 | 1 | 2 |
| Diabetic macular edema, n [17] | ||||
| Severe | 9 | 6 | 6 | 9 |
| Moderate | 11 | 7 | 4 | 1 |
| Mild | 4 | 7 | 8 | 5 |
| None | 2 | 6 | 8 | 11 |
Values in table are presented as the mean with the SD in parenthesis, unless indicated otherwise
n Number of participants (eyes) in that category